DK0654026T3 - Isoserinderivater og deres anvendelse som leukotrienantagonister - Google Patents

Isoserinderivater og deres anvendelse som leukotrienantagonister

Info

Publication number
DK0654026T3
DK0654026T3 DK93917564.2T DK93917564T DK0654026T3 DK 0654026 T3 DK0654026 T3 DK 0654026T3 DK 93917564 T DK93917564 T DK 93917564T DK 0654026 T3 DK0654026 T3 DK 0654026T3
Authority
DK
Denmark
Prior art keywords
pct
leukotriene antagonists
bromine
stands
chlorine
Prior art date
Application number
DK93917564.2T
Other languages
Danish (da)
English (en)
Inventor
Dorte Kirstein
Schneur Rachlin
Original Assignee
Leo Pharm Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharm Prod Ltd filed Critical Leo Pharm Prod Ltd
Application granted granted Critical
Publication of DK0654026T3 publication Critical patent/DK0654026T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK93917564.2T 1992-08-07 1993-08-05 Isoserinderivater og deres anvendelse som leukotrienantagonister DK0654026T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929216768A GB9216768D0 (en) 1992-08-07 1992-08-07 Chemical compounds

Publications (1)

Publication Number Publication Date
DK0654026T3 true DK0654026T3 (da) 1997-07-14

Family

ID=10719973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93917564.2T DK0654026T3 (da) 1992-08-07 1993-08-05 Isoserinderivater og deres anvendelse som leukotrienantagonister

Country Status (16)

Country Link
US (1) US5576438A (ko)
EP (1) EP0654026B1 (ko)
JP (1) JPH08504749A (ko)
KR (1) KR950701319A (ko)
AT (1) ATE149030T1 (ko)
AU (1) AU666967B2 (ko)
CA (1) CA2134565A1 (ko)
DE (1) DE69308212T2 (ko)
DK (1) DK0654026T3 (ko)
ES (1) ES2100550T3 (ko)
FI (1) FI950515A (ko)
GB (1) GB9216768D0 (ko)
GR (1) GR3023069T3 (ko)
NZ (1) NZ254741A (ko)
RU (1) RU2126389C1 (ko)
WO (1) WO1994003431A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414590D0 (en) * 1994-07-20 1994-09-07 Leo Pharm Prod Ltd Chemical compounds
GB9524185D0 (en) * 1995-11-27 1996-01-31 Leo Pharm Prod Ltd Substituted diols
FR2751969B1 (fr) * 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
KR20000044978A (ko) * 1998-12-30 2000-07-15 성재갑 각질 박리 촉진용 조성물
CN103044277B (zh) * 2013-01-07 2015-04-08 华东师范大学 光学纯α-羟基-β-氨基丙酸酯衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK282986A (da) * 1985-06-18 1987-02-24 Merck Frosst Canada Inc Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
US4962203A (en) * 1985-06-18 1990-10-09 Merck Frost Canada, Inc. 2-substituted quinolines useful as leukotriene antagonists
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
US5102881A (en) * 1988-06-27 1992-04-07 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
GB8919504D0 (en) * 1989-08-29 1989-10-11 Leo Pharm Prod Ltd Chemical compounds
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists

Also Published As

Publication number Publication date
WO1994003431A1 (en) 1994-02-17
RU2126389C1 (ru) 1999-02-20
EP0654026A1 (en) 1995-05-24
AU4698293A (en) 1994-03-03
FI950515A0 (fi) 1995-02-06
ES2100550T3 (es) 1997-06-16
DE69308212T2 (de) 1997-09-18
ATE149030T1 (de) 1997-03-15
JPH08504749A (ja) 1996-05-21
DE69308212D1 (de) 1997-03-27
EP0654026B1 (en) 1997-02-19
KR950701319A (ko) 1995-03-23
CA2134565A1 (en) 1994-02-17
FI950515A (fi) 1995-02-06
GR3023069T3 (en) 1997-07-30
AU666967B2 (en) 1996-02-29
US5576438A (en) 1996-11-19
NZ254741A (en) 1997-07-27
GB9216768D0 (en) 1992-09-23
RU94046453A (ru) 1996-09-27

Similar Documents

Publication Publication Date Title
FI932229A (fi) Azabicykliska bryggderivat
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
DE69217945D1 (de) Azanorbornanderivate
DK0941221T3 (da) Substituerede dihydrobenzofuraner som PDE-inhibitorer
DE69231445T2 (de) Triazole enthaltende antifungizide mittel
DK0654026T3 (da) Isoserinderivater og deres anvendelse som leukotrienantagonister
ATE153336T1 (de) Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
DE69711868D1 (de) Adenosin-derivate
NO179865C (no) Nytt -fenylisoserinderivat og dets fremstilling
ATE171939T1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
DK0668852T3 (da) Substituerede orthoethenylphenyleddikesyrederivater
DK0863876T3 (da) Quinolinderivater indeholdende en diol som leukotrienantagonister
DE59508928D1 (de) Saccharinderivate und ihre anwendung als herbizide
NO963367L (no) Nye mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
DE69425823D1 (de) Substituierte chinolinderivate, und ihre verwendung als inhibitoren der magensekretion
FI955707A (fi) Indolijohdannaiset steroidi-5alfa-reduktaasin inhibiittoreina
DK1501823T3 (da) Hidtil ukendte piperidinyl-alkylamino-pyridazinon-derivater, en fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder forbindelserne